Infliximab Injection Industry Research Report 2025
Description
Summary
According to APO Research, the global Infliximab Injection market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Infliximab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Infliximab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Infliximab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Infliximab Injection include Yuxi Jiahe Biotechnology, Taizhou Maiboteike Pharmaceuticals, Hangzhou Bozhirui Biopharmaceuticals, Pfizer, Nippon Kayaku, Nichiiko, Janssen Biologics, Celltrion and Ayumi Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Infliximab Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Infliximab Injection.
The report will help the Infliximab Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Infliximab Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Infliximab Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Infliximab Injection Segment by Company
Yuxi Jiahe Biotechnology
Taizhou Maiboteike Pharmaceuticals
Hangzhou Bozhirui Biopharmaceuticals
Pfizer
Nippon Kayaku
Nichiiko
Janssen Biologics
Celltrion
Ayumi Pharmaceuticals
AMGEN
Infliximab Injection Segment by Type
Original Drug
Generic Drug
Infliximab Injection Segment by Application
Hospital
Clinic
Other
Infliximab Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infliximab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infliximab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infliximab Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Infliximab Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Infliximab Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Infliximab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Infliximab Injection market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Infliximab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Infliximab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Infliximab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Infliximab Injection include Yuxi Jiahe Biotechnology, Taizhou Maiboteike Pharmaceuticals, Hangzhou Bozhirui Biopharmaceuticals, Pfizer, Nippon Kayaku, Nichiiko, Janssen Biologics, Celltrion and Ayumi Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Infliximab Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Infliximab Injection.
The report will help the Infliximab Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Infliximab Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Infliximab Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Infliximab Injection Segment by Company
Yuxi Jiahe Biotechnology
Taizhou Maiboteike Pharmaceuticals
Hangzhou Bozhirui Biopharmaceuticals
Pfizer
Nippon Kayaku
Nichiiko
Janssen Biologics
Celltrion
Ayumi Pharmaceuticals
AMGEN
Infliximab Injection Segment by Type
Original Drug
Generic Drug
Infliximab Injection Segment by Application
Hospital
Clinic
Other
Infliximab Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infliximab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infliximab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infliximab Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Infliximab Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Infliximab Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Infliximab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
129 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Infliximab Injection Market Size (2020-2031)
- 2.2.2 Global Infliximab Injection Sales (2020-2031)
- 2.2.3 Global Infliximab Injection Market Average Price (2020-2031)
- 2.3 Infliximab Injection by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 Original Drug
- 2.3.3 Generic Drug
- 2.4 Infliximab Injection by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Other
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Infliximab Injection Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Infliximab Injection Sales (K Units) of Manufacturers (2020-2025)
- 3.3 Global Infliximab Injection Revenue of Manufacturers (2020-2025)
- 3.4 Global Infliximab Injection Average Price by Manufacturers (2020-2025)
- 3.5 Global Infliximab Injection Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Infliximab Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Infliximab Injection, Product Type & Application
- 3.8 Global Manufacturers of Infliximab Injection, Established Date
- 3.9 Global Infliximab Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Yuxi Jiahe Biotechnology
- 4.1.1 Yuxi Jiahe Biotechnology Company Information
- 4.1.2 Yuxi Jiahe Biotechnology Business Overview
- 4.1.3 Yuxi Jiahe Biotechnology Infliximab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Yuxi Jiahe Biotechnology Infliximab Injection Product Portfolio
- 4.1.5 Yuxi Jiahe Biotechnology Recent Developments
- 4.2 Taizhou Maiboteike Pharmaceuticals
- 4.2.1 Taizhou Maiboteike Pharmaceuticals Company Information
- 4.2.2 Taizhou Maiboteike Pharmaceuticals Business Overview
- 4.2.3 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Product Portfolio
- 4.2.5 Taizhou Maiboteike Pharmaceuticals Recent Developments
- 4.3 Hangzhou Bozhirui Biopharmaceuticals
- 4.3.1 Hangzhou Bozhirui Biopharmaceuticals Company Information
- 4.3.2 Hangzhou Bozhirui Biopharmaceuticals Business Overview
- 4.3.3 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Product Portfolio
- 4.3.5 Hangzhou Bozhirui Biopharmaceuticals Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Infliximab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Pfizer Infliximab Injection Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 Nippon Kayaku
- 4.5.1 Nippon Kayaku Company Information
- 4.5.2 Nippon Kayaku Business Overview
- 4.5.3 Nippon Kayaku Infliximab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 Nippon Kayaku Infliximab Injection Product Portfolio
- 4.5.5 Nippon Kayaku Recent Developments
- 4.6 Nichiiko
- 4.6.1 Nichiiko Company Information
- 4.6.2 Nichiiko Business Overview
- 4.6.3 Nichiiko Infliximab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 Nichiiko Infliximab Injection Product Portfolio
- 4.6.5 Nichiiko Recent Developments
- 4.7 Janssen Biologics
- 4.7.1 Janssen Biologics Company Information
- 4.7.2 Janssen Biologics Business Overview
- 4.7.3 Janssen Biologics Infliximab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 Janssen Biologics Infliximab Injection Product Portfolio
- 4.7.5 Janssen Biologics Recent Developments
- 4.8 Celltrion
- 4.8.1 Celltrion Company Information
- 4.8.2 Celltrion Business Overview
- 4.8.3 Celltrion Infliximab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Celltrion Infliximab Injection Product Portfolio
- 4.8.5 Celltrion Recent Developments
- 4.9 Ayumi Pharmaceuticals
- 4.9.1 Ayumi Pharmaceuticals Company Information
- 4.9.2 Ayumi Pharmaceuticals Business Overview
- 4.9.3 Ayumi Pharmaceuticals Infliximab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 Ayumi Pharmaceuticals Infliximab Injection Product Portfolio
- 4.9.5 Ayumi Pharmaceuticals Recent Developments
- 4.10 AMGEN
- 4.10.1 AMGEN Company Information
- 4.10.2 AMGEN Business Overview
- 4.10.3 AMGEN Infliximab Injection Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 AMGEN Infliximab Injection Product Portfolio
- 4.10.5 AMGEN Recent Developments
- 5 Global Infliximab Injection Market Scenario by Region
- 5.1 Global Infliximab Injection Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Infliximab Injection Sales by Region: 2020-2031
- 5.2.1 Global Infliximab Injection Sales by Region: 2020-2025
- 5.2.2 Global Infliximab Injection Sales by Region: 2026-2031
- 5.3 Global Infliximab Injection Revenue by Region: 2020-2031
- 5.3.1 Global Infliximab Injection Revenue by Region: 2020-2025
- 5.3.2 Global Infliximab Injection Revenue by Region: 2026-2031
- 5.4 North America Infliximab Injection Market Facts & Figures by Country
- 5.4.1 North America Infliximab Injection Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Infliximab Injection Sales by Country (2020-2031)
- 5.4.3 North America Infliximab Injection Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Infliximab Injection Market Facts & Figures by Country
- 5.5.1 Europe Infliximab Injection Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Infliximab Injection Sales by Country (2020-2031)
- 5.5.3 Europe Infliximab Injection Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Infliximab Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Infliximab Injection Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Infliximab Injection Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Infliximab Injection Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Infliximab Injection Market Facts & Figures by Country
- 5.7.1 South America Infliximab Injection Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Infliximab Injection Sales by Country (2020-2031)
- 5.7.3 South America Infliximab Injection Revenue by Country (2020-2031)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Infliximab Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Infliximab Injection Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Infliximab Injection Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Infliximab Injection Revenue by Country (2020-2031)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
- 6 Segment by Type
- 6.1 Global Infliximab Injection Sales by Type (2020-2031)
- 6.1.1 Global Infliximab Injection Sales by Type (2020-2031) & (K Units)
- 6.1.2 Global Infliximab Injection Sales Market Share by Type (2020-2031)
- 6.2 Global Infliximab Injection Revenue by Type (2020-2031)
- 6.2.1 Global Infliximab Injection Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Infliximab Injection Revenue Market Share by Type (2020-2031)
- 6.3 Global Infliximab Injection Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Infliximab Injection Sales by Application (2020-2031)
- 7.1.1 Global Infliximab Injection Sales by Application (2020-2031) & (K Units)
- 7.1.2 Global Infliximab Injection Sales Market Share by Application (2020-2031)
- 7.2 Global Infliximab Injection Revenue by Application (2020-2031)
- 7.2.1 Global Infliximab Injection Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Infliximab Injection Revenue Market Share by Application (2020-2031)
- 7.3 Global Infliximab Injection Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Infliximab Injection Value Chain Analysis
- 8.1.1 Infliximab Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Infliximab Injection Production Mode & Process
- 8.2 Infliximab Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Infliximab Injection Distributors
- 8.2.3 Infliximab Injection Customers
- 9 Global Infliximab Injection Analyzing Market Dynamics
- 9.1 Infliximab Injection Industry Trends
- 9.2 Infliximab Injection Industry Drivers
- 9.3 Infliximab Injection Industry Opportunities and Challenges
- 9.4 Infliximab Injection Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
